18889881171
Kalkine 0
countryflagUS

AAPL 208.72 0.168% MSFT 388.5148 0.3137% NVDA 110.49 3.8147% GOOGL 162.58 2.0718% GOOG 164.7 2.0004% AMZN 187.93 0.7451% META 545.87 2.3858% AVGO 191.75 1.9134% LLY 870.695 1.2754% TSLA 285.6351 10.0671% TSM 164.7921 0.3728% V 334.98 -0.2174% JPM 243.11 -0.6254% UNH 418.56 -1.3412% NVO 61.81 -1.3093% WMT 94.725 -1.1634% LVMUY 114.14 -0.105% XOM 108.25 -0.3498% LVMHF 566.0 0.7347% MA 532.36 -0.5789%

Biostar Pharmaceuticals Inc

Healthcare US BSPM

0.0001USD
-(-%)

Last update at 2025-04-24T20:00:00Z

Day Range

0.00010.0001
LowHigh

52 Week Range

-0.0001
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.32M
  • Volume2400
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA3.89M
  • Revenue TTM0.32M
  • Revenue Per Share TTM0.12
  • Gross Profit TTM 0.92M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2016-12-31 2015-12-31 2014-12-31 2013-12-31 2012-12-31
Type yearly yearly yearly yearly yearly
Date 2016-12-31 2015-12-31 2014-12-31 2013-12-31 2012-12-31
Income before tax -3.04533M -23.79272M 1.53M 2.66M -21.57370M
Minority interest 0.00000M 0.00000M 0.00000M 0.00000M -
Net income -5.69839M -25.11256M 4.85M 0.81M -19.99732M
Selling general administrative 2.43M 4.65M 7.72M 6.09M 5.95M
Selling and marketing expenses 1.17M 8.64M 18.49M 16.58M 27.89M
Gross profit 0.92M 11.10M 30.28M 25.68M 29.85M
Reconciled depreciation - - - - -
Ebit -3.56426M -10.87165M 2.64M 2.43M -12.14080M
Ebitda -1.92370M -8.62711M 5.72M 5.21M -10.01620M
Depreciation and amortization 1.64M 2.24M 3.09M 2.79M 2.12M
Non operating income net other 0.00000M 0.00000M 0.00000M 0.00000M 0.30M
Operating income -3.56426M -10.87165M 2.64M 2.43M -12.14080M
Other operating expenses 5.95M 38.00M 60.11M 51.65M 61.46M
Interest expense 0.21M 0.28M 0.15M 0.37M 0.08M
Tax provision 2.65M - - - -
Interest income 0.00117M - - - -
Net interest income -0.20503M - - - -
Extraordinary items 0.00000M 0.00000M 0.00000M 0.00000M -
Non recurring -0.26549M 0.00000M 0.00000M -0.00000M 3.67M
Other items 0.00000M 0.00000M 0.00000M 0.00000M -
Income tax expense 2.65M 1.32M -3.31358M 1.85M -1.57638M
Total revenue 2.38M 27.13M 61.42M 52.73M 49.32M
Total operating expenses 4.48M 21.98M 28.97M 24.60M 41.99M
Cost of revenue 1.47M 16.03M 31.14M 27.05M 19.47M
Total other income expense net 0.52M -12.92106M -1.10083M 0.23M -9.43290M
Discontinued operations 0.00000M 0.00000M 0.00000M 0.00000M -
Net income from continuing ops -5.69839M -25.11256M 4.85M 0.81M -19.99732M
Net income applicable to common shares -5.69839M -25.11256M 4.85M 0.81M -19.99732M
Preferred stock and other adjustments 0.00000M 0.00000M 0.00000M 0.00000M -
Breakdown 2016-12-31 2015-12-31 2014-12-31 2013-12-31 2012-12-31
Type yearly yearly yearly yearly yearly
Date 2016-12-31 2015-12-31 2014-12-31 2013-12-31 2012-12-31
Total assets 42.50M 51.36M 81.25M 67.56M 70.48M
Intangible assets 5.61M 6.88M 13.27M 17.13M 9.14M
Earning assets - - - - -
Other current assets 0.00008M 0.00008M 4.42M 3.44M 3.65M
Total liab 5.62M 7.10M 8.91M 4.79M 12.70M
Total stockholder equity 36.88M 44.27M 72.34M 62.77M 57.77M
Deferred long term liab 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Other current liab 0.46M 0.06M 0.38M 0.34M 0.63M
Common stock 0.00264M 0.00221M 0.02M 0.01M 0.00999M
Capital stock - - - - -
Retained earnings -2.54099M 3.16M 28.27M 23.65M 23.23M
Other liab 0.00000M 0.00000M 0.00000M 0.00000M -
Good will 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Other assets 23.66M 21.51M 15.86M 6.72M 12.38M
Cash 0.17M 0.04M 1.69M 0.08M 1.76M
Cash and equivalents - - - - -
Total current liabilities 5.62M 7.10M 8.91M 4.79M 12.70M
Current deferred revenue - 0.11M 0.43M - -
Net debt 2.15M 2.73M 1.41M -0.08007M 4.58M
Short term debt 2.33M 2.77M 3.09M 0.00000M 6.34M
Short long term debt 2.33M 0.00000M 0.00000M 0.00000M -
Short long term debt total 2.33M 2.77M 3.09M - 6.34M
Other stockholder equity 31.38M 30.32M 30.30M 25.38M 23.27M
Property plant equipment 5.87M 6.81M 8.48M 7.73M 6.98M
Total current assets 7.37M 16.17M 43.63M 35.99M 41.97M
Long term investments 0.00000M 0.00000M 0.00000M 0.00000M -
Net tangible assets 31.27M 37.39M 59.07M 45.64M -
Short term investments 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Net receivables 7.03M 15.89M 36.85M 31.64M 35.72M
Long term debt 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Inventory 0.17M 0.23M 0.67M 0.83M 0.85M
Accounts payable 2.84M 4.15M 5.00M 4.45M 5.73M
Total permanent equity 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Noncontrolling interest in consolidated entity 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Temporary equity redeemable noncontrolling interests 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Accumulated other comprehensive income 8.04M 10.79M 13.75M 13.73M 11.27M
Additional paid in capital 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Common stock total equity 0.00264M 0.00221M 0.02M 0.01M 0.00999M
Preferred stock total equity 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings total equity -2.54099M 0.00000M 0.00000M 0.00000M 0.00000M
Treasury stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Accumulated amortization 0.00000M 0.00000M 0.00000M 0.00000M -
Non currrent assets other 21.15M 16.10M 8.80M 3.93M 8.72M
Deferred long term asset charges 0.00000M 0.00000M 0.00000M 0.00000M -
Non current assets total 35.14M 35.20M 37.61M 31.58M 28.50M
Capital lease obligations 0.00000M 0.00000M 0.00000M 0.00000M -
Long term debt total 0.00000M 0.00000M 0.00000M 0.00000M -
Breakdown 2016-12-31 2015-12-31 2014-12-31 2013-12-31 2012-12-31
Type yearly yearly yearly yearly yearly
Date 2016-12-31 2015-12-31 2014-12-31 2013-12-31 2012-12-31
Investments -6.37814M 0.00000M 0.00000M 0.00000M -
Change to liabilities -1.08735M -0.60296M 0.57M -1.44944M 1.01M
Total cashflows from investing activities -6.37814M -7.37753M -8.87814M -4.21079M -17.28879M
Net borrowings -0.27831M -0.16084M 3.09M -6.45755M 5.55M
Total cash from financing activities 1.41M -0.16084M 6.95M -6.45755M 5.55M
Change to operating activities -0.32968M 0.08M 0.33M -0.46302M -
Net income -5.69839M -25.11256M 4.85M 0.81M -19.99732M
Change in cash 0.13M -1.64626M 1.61M -1.67901M -15.21271M
Begin period cash flow 0.04M 1.69M 0.08M 1.76M 16.97M
End period cash flow 0.17M 0.04M 1.69M 0.08M 1.76M
Total cash from operating activities 4.91M 5.88M 3.31M 8.91M -3.58369M
Issuance of capital stock - - - - -
Depreciation 1.14M 2.32M 3.09M 2.79M 1.83M
Other cashflows from investing activities -6.37814M -0.00000M -0.00000M -0.00000M -17.25592M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory 0.06M 0.42M 0.15M 0.04M 0.54M
Change to account receivables 8.67M 5.45M -7.44145M 4.20M 6.63M
Sale purchase of stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Other cashflows from financing activities -6.37814M -7.37753M 3.25M -4.21079M 6.34M
Change to netincome 2.16M 22.26M 1.45M 3.08M 3.81M
Capital expenditures 0.00000M 0.06M 2.87M 0.98M 0.03M
Change receivables 8.67M 0.00000M -0.00000M 0.00000M 6.63M
Cash flows other operating -0.17629M 0.00000M -0.00000M -0.00000M 2.61M
Exchange rate changes 0.00000M 0.00000M 0.00000M 0.00000M 0.11M
Cash and cash equivalents changes 0.00000M -0.00000M 0.00000M -0.00000M -15.21271M
Change in working capital 7.31M 5.35M -6.07586M 2.24M 6.30M
Stock based compensation -0.26549M 17.97M 2.02M 0.76M 0.82M
Other non cash items -0.22711M 4.02M 3.72M 1.34M 9.50M
Free cash flow 4.91M 5.82M 0.44M 7.93M -3.61656M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BSPM
Biostar Pharmaceuticals Inc		 - -% 0.0001 - - 1.00 0.009 1.00 0.06
ZTS
Zoetis Inc		 -0.1452 0.10% 152.15 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.25 0.90% 27.59 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 133.19 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.095 0.63% 15.02 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.

Biostar Pharmaceuticals Inc

No. 588 Shiji Xi Road, Xianyang, China, 712000

Key Executives

Name Title Year Born
Mr. Ronghua Wang Chairman, CEO & Pres 1956
Mr. Zhenghong Wang Chief Operating Officer 1980
Ms. Xiaojuan Zhai Chief Financial Officer 1989
Prof. Xiaohui Zheng Chief Scientist 1968
Ms. Shuang Gong Director of Admin. & Sec. of Board 1967
Mr. Ronghua Wang Chairman, CEO & President 1956
Ms. Shuang Gong Director of Administration & Secretary of Board 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.